http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021102258-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_86a5e4074201ca7cb9fb478680c057be |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-329 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57488 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
filingDate | 2020-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09e6cf350a7bebf8c307d04ee0db6a3f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d9d4e4a476c8cd7ac780c44b5fbc04e |
publicationDate | 2021-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-2021102258-A1 |
titleOfInvention | Diagnostic blood test |
abstract | The present application provides an in vitro method for determining the degradation of the extracellular matrix (ECM) in a subject, the method comprising determining in an isolated sample from the subject the level of an expression product of at least one gene selected from the group consisting of collagen type V alpha 1 chain (COL5A1), transforming growth factor beta-1 (TGFB1), integrin subunit alpha 4 (ITGA4), integrin subunit beta 1 (ITGB1), matrix metallopeptidase 2 (MMP2), matrix metallopeptidase 9 (MMP9) and bone morphogenetic protein 1 (BMP1), the at least one gene being determined optionally in combination with one or both of collagen type XI alpha 1 chain (COL11A1) and collagen type V alpha 2 chain (COL5A2), wherein when the level of the expression product(s) is(are) higher than a reference value this is indicative of a degraded ECM. Methods for the diagnosis and prognosis of cancer and aneurysms are also provided. Furthermore, means for determining the level of expression product of the genes in the above diagnosis or prognosis methods are also provided, as well as kits containing said means. |
priorityDate | 2018-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 158.